BCYC

SEC filing BCYC Reports Encouraging Initial Duravelo-2 Data: 65% ORR, 58% Confirmed ORR, Lower Toxicity vs SOC in Metastatic Urothelial Cancer Trial

11d ago

News Wall Street Analysts Think Bicycle Therapeutics (BCYC) Could Surge 85.52%: Read This Before Placing a Bet

14d ago

News Bicycle Therapeutics (BCYC) Up as PIPE Funding Set to Make $555M

14d ago

Insider trade Sale by Michael Skynner (CHIEF SCIENTIFIC OFFICER)

56d ago

Insider trade Sale by Kevin Lee (CHIEF EXECUTIVE OFFICER)

56d ago

Insider trade Sale by Jennifer Scott Perry (Chief Operating Officer)

56d ago

Insider trade Sale by Travis Alvin Thompson (Chief Financial Officer)

56d ago

Insider trade Sale by Michael Charles Ferguson Hannay (CHIEF PROD & SUPPLY CHAIN OFF)

56d ago

SEC filing BCYC Reports $628M Cash, $65M Q4 Rev, +15% YoY, Announces Workforce Cut 30%, Focuses on BT5528, Duravelo-2 Converted to Phase 2, Cash Runway to 2030

77d ago

Scanner Unusual volume (3.4x average)

125d ago

News Bicycle Therapeutics Establishes Multiple Strategic Partnerships to Create End-to-End Supply Chain to Support its Wholly Owned Radiopharmaceutical Pipeline – Company Announcement - FT.com

168d ago